AmerisourceBergen has added $50 million more to resolve a DOJ probe into sales of cancer meds, taking its total in the matter to $885 million.
AmerisourceBergen will extend its reach with an $815 million deal to buy independent drug distributor H. D. Smith.
Facing a rash of lawsuits claiming aggressive opioid marketing led to a nationwide epidemic, Purdue Pharma is reportedly initiating settlement talks.
AmerisourceBergen's costs to resolve federal litigation tied to syringe sold from an unregistered facility may reach $835 million
Generic drug prices have continued their downward spiral, but one distributor sees light at the end of the tunnel.
Investors are demanding change at top drug distributors after an investigation exposed lax controls and lots of Capitol Hill arm-twisting.
AmerisourceBergen has pled guilty and agreed to pay $260 million to settle a federal case over its sales of cancer meds from an unregistered facility.
After years of going it alone in investigating opioid drugmakers, attorneys general across the U.S. are joining forces to drill into painkiller marketing practices.
AmerisourceBergen has finally come to the table to resolve a federal kickback lawsuit that Novartis settled two years ago for nearly $400 million.
AmerisourceBergen said the industry can expect branded prices to continue to rise 7% to 9%, while generics prices will keep sliding, off 7% to 9%.